Nivolumab in Chemotherapy-Resistant Cervical Cancer: Report of a Vulvitis as a Novel Immune-Related Adverse Event and Molecular Analysis of a Persistent Complete Response

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/s40425-019-0742-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Pericardial Effusion With Tamponade, an Immune-Related Adverse Event Associated With Nivolumab Therapy: A Case Report and Review of the Literature

Journal of Cancer Therapy
2018English

819 Extragenital Lichen Sclerosus Is an Immune-Related Adverse Event With Nivolumab

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-Related Adverse Events

Radiographics
MedicineNuclear MedicineRadiologyImaging
2015English

Delayed Immune-Related Erythrodermia in a Squamous NSCLC Patient Treated With Nivolumab: A Case Report

Journal of Cancer Research and Immuno-Oncology
2018English

A Case of Advanced Gastric Cancer Achieved a Pathological Complete Response by Chemotherapy

Surgical Case Reports
2017English

A Novel Adverse Event of Nusinersen Treatment: Thrombocytosis

Indian Journal of Pediatrics
Child HealthPediatricsPerinatology
2019English

Clinical Complete Response From Chemotherapy in an Elderly Patient With Metastatic Gastric Cancer: A Case Report

Journal of Nippon Medical School
Medicine
2016English

Pathological Complete Response After Neoadjuvant Chemotherapy With Trastuzumab-Containing Regimen in Gastric Cancer: A Case Report

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy